Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shot up 3.6% during trading on Wednesday . The stock traded as high as $82.50 and last traded at $79.76. 1,243,617 shares changed hands during mid-day trading, an increase of 557% from the average session volume of 189,291 shares. The stock had previously closed at $77.01.
Gemini Therapeutics Stock Up 3.6%
The company has a market capitalization of $3.46 billion, a price-to-earnings ratio of -79.76 and a beta of -0.12. The stock’s 50-day simple moving average is $69.81 and its two-hundred day simple moving average is $70.13.
About Gemini Therapeutics
Gemini Therapeutics (NASDAQ:GMTX) is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company’s approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.
Gemini’s lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
